Cargando…

Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan

PURPOSE: Patients with hematological malignancies are at an increased risk of severe infection with coronavirus disease 2019 (COVID-19). However, developing an adequate immune response after vaccination is difficult, especially in patients with lymphoid neoplasms. Since the long-term effects of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marumo, Yoshiaki, Yoshida, Takashi, Furukawa, Yuki, Ina, Kenji, Kamiya, Ayumi, Kataoka, Takae, Kayukawa, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Vaccine Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655153/ https://www.ncbi.nlm.nih.gov/pubmed/38025915 http://dx.doi.org/10.7774/cevr.2023.12.4.319

Ejemplares similares

Diagnosis of a SMARCA4 ‐deficient undifferentiated tumor using multigene panel testing: A case report
por: Marumo, Yoshiaki, et al.
Publicado: (2023)

Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2
por: Kayukawa, Satoshi, et al.
Publicado: (2021)

Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases
por: Ina, Kenji, et al.
Publicado: (2016)

Bladder squamous cell cancer accompanied by Trousseau's syndrome: a case report
por: Kayukawa, Satoshi, et al.
Publicado: (2018)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds
por: Ribak, Yaarit, et al.
Publicado: (2023)

POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS
por: Yau, K., et al.
Publicado: (2022)

Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
por: Yoshimura, Yukihiro, et al.
Publicado: (2021)

Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
por: Nakazawa, Hideyuki, et al.
Publicado: (2022)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
por: Igari, Hidetoshi, et al.
Publicado: (2022)

Antibody titres decline 3-month post-vaccination with BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Serological Response to BNT162b2 Anti-Sars-Cov-2 mRNA Vaccine in Patients with Transfusion Dependent Thalassemia
por: Zucano, Stefania, et al.
Publicado: (2021)

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
por: Goshen-Lago, Tal, et al.
Publicado: (2021)

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
por: Enssle, Julius C., et al.
Publicado: (2022)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

The Use of Lentinan for Treating Gastric Cancer
por: Ina, Kenji, et al.
Publicado: (2013)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey
por: Nishikimi, Akihiko, et al.
Publicado: (2022)

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas
por: Marchesi, Francesco, et al.
Publicado: (2021)

Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases
por: Edelman-Klapper, Hadar, et al.
Publicado: (2023)

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
por: Gurion, Ronit, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
por: Mitsunaga, Toshiya, et al.
Publicado: (2021)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan
por: Nishikimi, Akihiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ttah4fdj1ncfhicavmimf6jemp